Advion BioServices First to Offer SISCAPA Assay Services for Biomarker Assays
News Aug 01, 2011
Advion BioServices, a subsidiary of Advion BioSciences, Inc. and a leading bioanalytical contract research organization, will immediately begin offering its clients SISCAPA® LC/MS Biomarker assay services.
This is made possible by a license and collaboration agreement Advion BioServices has executed with SISCAPA Assay Technologies, Inc. of Rockville, MD.
Biomarker and in-turn, biotherapeutic analysis is a growing focus area in companion diagnostics, clinical patient profiling and drug development for pharmaceutical and biotechnology companies.
“Advion is a leader in bioanalytical services, and strives to offer cutting edge technology and the greatest value and resources to our clients,” comments Tom Kurz, Advion BioServices’ President.
He continues, “By partnering with SISCAPA Assay Technologies, Inc., we are able to leverage our expertise in protein and peptide analysis by mass spectrometry and open new areas of testing for our clients.”
Advion has a strong reputation in the industry for providing a large suite of critical bioanalytical services based on a philosophy of scientific excellence in an environment of strict regulatory compliance.
The SISCAPA assays are mass spectrometry-based, and will be conducted in Advion’s LC/MS laboratory, based in Ithaca, NY.
“We are very pleased that Advion BioServices has become the first CRO able to offer commercial SISCAPA assay services", said Leigh Anderson, CEO of SISCAPA Assay Technologies, Inc.
Anderson continued, "Advion is a recognized leader in mass spectrometric assays for peptides and proteins, and this capability provides a smooth path for implementation of novel biomarker assays in regulated pharmaceutical studies."
Since Darwin's era, scientists have wondered how flightless birds like emus, ostriches, kiwi, cassowaries and others are related, and for decades the assumption was that they must all share a common ancestor who abandoned the skies for a more grounded life. A team of Harvard researchers believes they may now have part of the answer.READ MORE